Beyond tamoxifen: New endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention

Annals of the New York Academy of Sciences

Volumn 952, Issue , 2001, Pages 44-59

  Fabian, Carol J ^a   Kimler, Bruce F ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Breast cancer; Breast cancer prevention agents; Selective estrogen receptor modulators; Tamoxifen

Indexed keywords

ANGIOGENESIS INHIBITOR; AROMATASE INHIBITOR; ARZOXIFENE; CYCLOOXYGENASE 2 INHIBITOR; DELTANOID; DEMETHYLATING AGENT; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR; FENRETINIDE; GONADORELIN; HISTONE DEACETYLASE INHIBITOR; ISOFLAVONE DERIVATIVE; METALLOPROTEINASE INHIBITOR; POLYAMINE SYNTHESIS INHIBITOR; RETINOID; REXINOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ASPIRATION BIOPSY; BREAST CANCER; BREAST HYPERPLASIA; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYAMINE SYNTHESIS; PRECANCER; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SIDE EFFECT;

EID: 0035687514     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb02727.x     Document Type: Conference Paper

References (113)

1. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
2. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1
3. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
4. Immunohistologic analysis of estrogen receptor expression in breast carcinoma precursor lesions
5. The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol
6. Indicators of increased breast cancer risk in humans
7. Mammary intraepithelial neoplasia: A translational classification system for the intraductal epithelial proliferations
8. Morphofunctional features of intraductal hyperplasia, atypical intraductal hyperplasia, and various grades of intraductal carcinoma
9. Extracellular matrix-resident basic fibroblast growth factor: Implications for control of angiogenesis
10. Interaction with endothelial cells is a prerequisite for branching ductal-alveolar morphogenesis and hyperplasia of preneoplastic human breast epithelial cells: Regulation of estrogen
11. Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast
12. Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast. Correlations with their functions as receptors and cell adhesion molecules
13. Estrogen receptor expression of benign breast epithelium and its association with breast cancer
14. Aromatase expression in the human breast
15. Metalloproteinases: Role in breast carcinogenesis, invasion and metastasis
16. Transforming growth factor alpha in epithelial proliferative diseases of the breast
17. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy
18. Altered expression of a structural protein (fodrin) within epithelial proliferation disease of the breast
19. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci
20. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer
21. Methylation and silencing of the retinoic acid receptor-B2 gene in breast cancer
22. Loss of p16INK4 expression of methylation is associated with lifespan extension of human mammary epithelial cells
23. Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia
24. Numerical abnormalities of chromosomes 7, 18, and X in precancerous breast disease defined by fluorescent in situ hybridization
25. Loss of heterozygosity at 3p in benign lesions preceding invasive breast cancer
26. Molecular analysis of premalignant and carcinoma in situ lesions of the human breast
27. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: Implications for tumorigenesis
28. A hypersensitive estrogen receptor-α mutation in premalignant breast lesions
29. Determinants of tissue estradiol levels and biologic responsiveness in breast tumors
30. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation
31. Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma
32. Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts
33. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and postmenopausal breast cancer patients
34. Expression of epidermal growth factor receptor mRNA and protein in primary breast cancers
35. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
36. Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression
37. Regulation of estrogen receptor-alpha gene expression by epidermal growth factor
38. Expression of cyclo-oxygenase-1 and cyclo-oxygenase-2 in human breast cancer
39. Cyclooxygenase-2 inhibitors in tumorogenesis part I
40. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth
41. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor
42. Immunohistochemical distribution and type IV collagenase in normal, benign, and malignant breast tissue
43. Cathepsin D, and epidermal growth factor in human breast cyst fluid
44. Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors
45. Microvessel quantification as a measure of angiogenic activity in benign breast tissue lesions: A marker for precancerous disease?
46. Proliferating cell nuclear antigen in breast lesions: Correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer
47. Insulin-like growth factor-1 receptors are overexpressed and predict a low risk in human breast cancer
48. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo
49. Biomarkers in benign breast disease: Risk factors for breast cancer
50. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells
51. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression
52. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer
53. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland
54. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation
55. Selective estrogen receptor modulators: Structure, function and clinical use
56. Efficacy and safety of two doses of the selective estrogen receptor modulator (SERM) Ly353381 in locally advanced or metastatic breast cancer (LAMBC) - A randomized double blind phase 2 study
57. Effects of soy isoflavones on estrogen and photoestrogen metabolism in premenopausal women
58. Soy consumption alters endogenous estrogen metabolism in postmenopausal women
59. Inhibition of human aromatase by mammalian lignans and isoflavnoid phytoestrogens
60. Decreased ovarian hormones during a soya diet: Implications for breast cancer prevention
61. Lessons from the use of aromatase inhibitors in the neoadjuvant setting
62. Study of the biological effects of the aromatase inhibitor letrazole in healthy postmenopausal women: Rationale for prevention
63. Preliminary results of two multi-center trials comparing the efficacy and tolerability of Arimidex™ (anastrozole) and tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC)
64. Safety of a gonadotrophin-releasing hormone agonist (GnRHA)-based hormonal chemoprevention for young women at high genetic risk for breast cancer
65. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
66. Progressive decrease in nuclear retinoic acid receptor β messenger RNA level during breast carcinogenesis
67. Cellular retinol-binding protein expression and breast cancer
68. Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) cause complete regression of mammary carcinoma
69. A ligand of peroxisome proliferator-activated receptor γ, retinoids and prevention of preneoplastic mammary lesions
70. 1α, 25-dihydroxy-vitamin D3 down regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells
71. A randomized trial of fenretinide in HRT users using IGF-1 as a surrogate biomarker
72. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo
73. Inhibitors of tyrosine kinase
74. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor
75. Histone deacetylase inhibitors: Inducers of differentiation of apoptosis of transformed cells
76. Matrix metalloproteinases: Biologic activity and clinical implications
77. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors
78. Phase I and pharmacokinetic studies of angiozyme, a synthetic ribozyme targeting the VEGF receptor Flt-1
79. Prevention and therapy of mammary cancer by monoterpenes
80. Phase I clinical trial of perillyl alcohol administered daily
81. Activation of the transforming growth factor β signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol
82. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent
83. Sulfone metabolite of sulindac inhibits mammary carcinogenesis
84. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention
85. Mammographic densities and breast cancer risk
86. Mammographic patterns as a predictive biomarker of breast cancer risk: Effect of tamoxifen
87. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients
88. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
89. Models for early chemoprevention trials in breast cancer
90. Effect of raloxifene on Ki67 and apoptosis
91. Antiproliferative effects of Idoxifene in a placebo-controlled trial in primary human breast cancer
92. A partially-blind, randomised, multicentre study comparing the anti-tumor effects of single doses (50, 125, and 250 mg) of long-acting (LA) 'faslodex' (ICI 182,780) with tamoxifen in postmenopausal women with primary breast cancer prior to surgery
93. rd generation selective estrogen receptor modulator, SERM) in breast cancer
94. Yield of terminal ductal lobule units (TDLU) in normal breast stereotactic core biopsy specimens: Implications of biomarker studies
95. Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy
96. Nipple aspirate fluid: A promising non-invasive method to identify cellular markers of breast cancer risk
97. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer
98. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model
99. Phase II chemoprevention trial of (α-Difluoromethylornithine (DFMO) in women at high risk for breast cancer: Surrogate endpoint biomarkers
100. No detectable improvement in clinical parameters or increased side effects in a placebo-controlled phase II breast chemoprevention trial of (α-difluromethylornithine (DFMO)
101. Prospective evaluation of radiologically directed fine-needle aspiration biopsy of nonpalpable breast lesions
102. Quantitation of preinvasive neoplastic progression in animal models of chemical carcinogenesis
103. Breast cytology results from serial fine needle aspiration (FNA) in a high risk population
104. LY33381 ·HCl: A novel raloxifene analogue with improved SERM potency and efficacy in vivo
105. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a Phase III randomized trial
106. Anastrozole (arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (Abc) in postmenopausal (Pm) women - Combined analysis from two identically designed multicenter trials
107. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
108. ZD1839 (Iressa™) an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, inhibits proliferation in normal and preinvasive breast epithelia
109. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study
110. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2
111. A potent specific pure antiestrogen with clinical potential
112. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover
113. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue